Total Payments
$117,706
2024 Payments
$3,228
Companies
18
Transactions
199
Medicare Patients
2,027
Medicare Billing
$362,396
Payment Breakdown by Category
Other$80,205 (68.1%)
Research$20,094 (17.1%)
Consulting$8,700 (7.4%)
Travel$5,364 (4.6%)
Food & Beverage$2,966 (2.5%)
Education$375.99 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $80,205 | 31 | 68.1% |
| Unspecified | $20,094 | 46 | 17.1% |
| Consulting Fee | $8,700 | 9 | 7.4% |
| Travel and Lodging | $5,364 | 12 | 4.6% |
| Food and Beverage | $2,966 | 97 | 2.5% |
| Education | $375.99 | 4 | 0.3% |
Payments by Type
General
$97,612
153 transactions
Research
$20,094
46 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $91,565 | 96 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $11,154 | 40 | $0 (2024) |
| PFIZER INC. | $9,853 | 16 | $0 (2024) |
| Janssen Biotech, Inc. | $3,180 | 26 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $930.00 | 1 | $0 (2022) |
| Alnylam Pharmaceuticals Inc. | $400.00 | 1 | $0 (2019) |
| COMSORT, Inc | $150.00 | 1 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $99.00 | 1 | $0 (2021) |
| Stemline Therapeutics Inc. | $69.38 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $64.42 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,228 | 25 | Regeneron Pharmaceuticals, Inc. ($2,937) |
| 2023 | $3,959 | 23 | Regeneron Pharmaceuticals, Inc. ($2,946) |
| 2022 | $4,323 | 13 | Regeneron Pharmaceuticals, Inc. ($3,298) |
| 2021 | $18,895 | 17 | Celgene Corporation ($13,277) |
| 2020 | $24,926 | 18 | Celgene Corporation ($16,044) |
| 2019 | $25,809 | 31 | Celgene Corporation ($25,299) |
| 2018 | $20,510 | 44 | Celgene Corporation ($20,180) |
| 2017 | $16,056 | 28 | Celgene Corporation ($15,967) |
All Payment Transactions
199 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/15/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Oncology | ||||||
| 10/20/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.74 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $446.23 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $388.00 | Research |
| Study: REGN5458 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $295.62 | Research |
| Study: REGN5458 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $280.54 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 07/09/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $141.41 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 06/14/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $310.40 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 06/07/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/07/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $1.50 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/03/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $310.40 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 05/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $27.08 | General |
| Category: Hematology | ||||||
| 05/17/2024 | Legend Biotech USA Inc. | — | Food and Beverage | In-kind items and services | $25.01 | General |
| 04/24/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $83.33 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 04/23/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $232.80 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 04/23/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $116.66 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 04/21/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $31.36 | General |
| Category: Oncology | ||||||
| 04/19/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 04/05/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $25.22 | General |
| Category: ONCOLOGY | ||||||
| 04/03/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $181.12 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 03/24/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $150.88 | Research |
| Study: PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | ||||||
| 03/18/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $25.68 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: Oncology | ||||||
| 01/29/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | Regeneron Pharmaceuticals, Inc. | $10,471 | 38 |
| TAFAMIDIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,940 | 6 |
| REGN5458 CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $683.62 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 422 | 912 | $390,057 | $99,521 |
| 2022 | 5 | 565 | 1,050 | $384,488 | $96,982 |
| 2021 | 6 | 527 | 1,093 | $335,827 | $88,582 |
| 2020 | 8 | 513 | 1,078 | $342,517 | $77,310 |
Total Patients
2,027
Total Services
4,133
Medicare Billing
$362,396
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 158 | 415 | $178,035 | $45,897 | 25.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 127 | 324 | $138,996 | $36,497 | 26.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 78 | 114 | $34,086 | $8,504 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 31 | 31 | $20,460 | $4,606 | 22.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $18,480 | $4,017 | 21.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 108 | 197 | $84,513 | $23,650 | 28.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 91 | 187 | $80,223 | $22,726 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 151 | 311 | $92,989 | $22,524 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 114 | 237 | $70,863 | $16,661 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 33 | 33 | $21,780 | $4,766 | 21.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 25 | 25 | $16,500 | $3,242 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 32 | 40 | $7,720 | $1,813 | 23.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 11 | 20 | $9,900 | $1,601 | 16.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 154 | 396 | $118,404 | $31,924 | 27.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 127 | 328 | $98,072 | $26,746 | 27.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 60 | 115 | $22,195 | $6,454 | 29.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 70 | 103 | $19,879 | $4,551 | 22.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 29 | 29 | $19,140 | $4,415 | 23.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 27 | 27 | $17,820 | $4,085 | 22.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 19 | 27 | $11,583 | $3,494 | 30.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 24 | $10,296 | $2,978 | 28.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 27 | $10,773 | $2,430 | 22.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 12 | 17 | $7,665 | $1,505 | 19.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 154 | 434 | $129,766 | $29,814 | 23.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 141 | 359 | $107,341 | $24,050 | 22.4% |
About Dr. James Hoffman, M.D
Dr. James Hoffman, M.D is a Internal Medicine healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2008. The National Provider Identifier (NPI) number assigned to this provider is 1427214147.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Hoffman, M.D has received a total of $117,706 in payments from pharmaceutical and medical device companies, with $3,228 received in 2024. These payments were reported across 199 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($80,205).
As a Medicare-enrolled provider, Hoffman has provided services to 2,027 Medicare beneficiaries, totaling 4,133 services with total Medicare billing of $362,396. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Miami, FL
- Active Since 08/01/2008
- Last Updated 02/15/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1427214147
Products in Payments
- Revlimid (Drug) $62,645
- VYNDAQEL (Drug) $9,699
- DARZALEX (Biological) $2,958
- KEYTRUDA (Biological) $150.00
- Pomalyst (Drug) $142.82
- IMBRUVICA (Drug) $127.77
- ELZONRIS (Drug) $69.38
- ELREXFIO (Drug) $58.68
- REBLOZYL (Biological) $57.17
- BOSULIF (Drug) $55.93
- CARVYKTI (Drug) $54.15
- clonoSEQ (Device) $50.90
- EMPLICITI (Biological) $45.89
- ADCETRIS (Biological) $41.56
- BESPONSA (Biological) $39.39
- SARCLISA (Biological) $29.17
- IMFINZI (Drug) $27.41
- TECVAYLI (Biological) $25.00
- Kyprolis (Drug) $21.78
- Kyprolis (Biological) $18.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Miami
Jay Skyler, Md, MD
Internal Medicine — Payments: $2.9M
Internal Medicine $2.9M
Dr. Lukasz Kwapisz
Internal Medicine — Payments: $800,664
Internal Medicine $800,664
Mark Kutner, Md, MD
Internal Medicine — Payments: $610,516
Internal Medicine $610,516
Dr. Ian Del Conde Pozzi, M.d, M.D
Internal Medicine — Payments: $499,756
Internal Medicine $499,756
Mr. Angel Carrasco, M.d, M.D
Internal Medicine — Payments: $493,362
Internal Medicine $493,362
Dr. Edward Mezerhane, Md, MD
Internal Medicine — Payments: $470,504
Internal Medicine $470,504